SEC Comment Letter for enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053) (NVNO) — Apr 14, 2020
enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053)
Date: April 14, 2020 · CIK: 0001661053 · Accession: 0000000000-20-003210
AI Filing Summary & Sentiment
File numbers found in text: 333-237592
Letter
April 14, 2020 Robert A. Berman Chief Executive Officer Hancock Jaffe Laboratories, Inc. 70 Doppler Irvine, CA 92618 Re:Hancock Jaffe Laboratories, Inc. Registration Statement on Form S-3 Filed April 7, 2020 File No. 333-237592 Dear Mr. Berman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Barry I. Grossman, Esq.
Show Raw Text
April 14, 2020
Robert A. Berman
Chief Executive Officer
Hancock Jaffe Laboratories, Inc.
70 Doppler
Irvine, CA 92618
Re:Hancock Jaffe Laboratories, Inc.
Registration Statement on Form S-3
Filed April 7, 2020
File No. 333-237592
Dear Mr. Berman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Barry I. Grossman, Esq.